MultiCenter Study to Assess the Safety and Effects of Autologous AdiposeDerived Stromal Cells in Patients with COPD

COPD or CHRONIC OBSTRUCTIVE PULMONARY DISEASE refers to a group of progressive lung diseases that can cause chest tightness, shortness of breath (respiratory difficulty), wheezing, and other symptoms. It is estimated that this disease affect 65 million people worldwide, according to the World Health Organization.

COPD is considered a major cause of disability and the third leading cause of death in the United States; affecting more likely people aged 65-74 years, current or former smokers and patients with history of asthma. Treatments for this disease include medications, smoking cessation, lung therapy and surgery (lung volume reduction and lung transplant). Tobacco smoking, exposures to fumes in the work place or home and episodes of respiratory infections are considered as key factors of the development and progression of COPD. The former factors cause inflammation of the respiratory tract which can lead to the beginning of the symptoms. Recent studies have shown that the Stem Cells have anti-inflammatory effects, giving the Stem Cells therapy potential for the improvement of the pulmonary function of COPD patients. 


• No risk of allergic or adverse reaction

• Little to no downtime, a safe and fast recovery